ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia - Systematic review and meta-analysis

Anat Gafter-Gvili, Ron Ram, Ronit Gurion, Mical Paul, Moshe Yeshurun, Pia Raanani, Ofer Shpilberg

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background: Immunosuppression is the therapeutic alternative for patients with aplastic anemia who are ineligible for allogeneic transplant. We aimed to assess the benefit of the combination of antithymocyte globulin (ATG) and cyclosporine (CsA). Methods: We performed a systematic review and meta-analysis of all randomized controlled trials that compared ATG and CsA to ATG alone as first-line treatment for patients with severe and nonsevere aplastic anemia. The Cochrane Library, Medline, conference proceedings and references were searched until 2008. Relative risks (RR) with 95% confidence intervals (CIs) were estimated for each trial and pooled. Results: Our search yielded 4 trials. For patients with severe aplastic anemia, there was a significant reduction in mortality in the ATG and CsA arm, which began at 3 months (RR = 0.50, 95% CI 0.29-0.85) and was maintained over a long follow-up of 5 years (RR = 0.58, 95 % CI 0.36-0.93). Conversely, in patients with nonsevere aplastic anemia, there was no difference in mortality. Conclusions: The combination of both drugs should be considered the gold standard only for patients with severe aplastic anemia.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalActa Haematologica
Volume120
Issue number4
DOIs
StatePublished - 1 Mar 2009
Externally publishedYes

Keywords

  • Antithymocyte globulin
  • Aplastic anemia
  • Cyclosporine

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia - Systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this